Annual Operating Expenses
$132.18 M
+$34.93 M+35.92%
December 31, 2023
Summary
- As of February 7, 2025, TRDA annual total operating expenses is $132.18 million, with the most recent change of +$34.93 million (+35.92%) on December 31, 2023.
- During the last 3 years, TRDA annual operating expenses has risen by +$105.51 million (+395.65%).
- TRDA annual operating expenses is now at all-time high.
Performance
TRDA Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$41.23 M
-$43.00 K-0.10%
September 30, 2024
Summary
- As of February 7, 2025, TRDA quarterly total operating expenses is $41.23 million, with the most recent change of -$43.00 thousand (-0.10%) on September 30, 2024.
- Over the past year, TRDA quarterly operating expenses has increased by +$11.51 million (+38.71%).
- TRDA quarterly operating expenses is now -0.10% below its all-time high of $41.27 million, reached on June 30, 2024.
Performance
TRDA Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
TRDA Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +35.9% | +38.7% |
| 3 y3 years | +395.6% | +61.2% |
| 5 y5 years | +1017.9% | +61.2% |
TRDA Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +158.5% | -0.1% | +123.3% |
| 5 y | 5-year | at high | +1017.9% | -0.1% | +491.3% |
| alltime | all time | at high | +1017.9% | -0.1% | +491.3% |
Entrada Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $41.23 M(-0.1%) |
| Jun 2024 | - | $41.27 M(+8.6%) |
| Mar 2024 | - | $38.01 M(+2.9%) |
| Dec 2023 | $132.18 M(+35.9%) | $36.94 M(+24.3%) |
| Sep 2023 | - | $29.72 M(-13.8%) |
| Jun 2023 | - | $34.47 M(+11.0%) |
| Mar 2023 | - | $31.04 M(+21.3%) |
| Dec 2022 | $97.25 M | $25.58 M(-1.4%) |
| Sep 2022 | - | $25.94 M(+10.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $23.58 M(+6.5%) |
| Mar 2022 | - | $22.15 M(+20.0%) |
| Dec 2021 | $51.13 M(+91.7%) | $18.46 M(+28.5%) |
| Sep 2021 | - | $14.36 M(+44.9%) |
| Jun 2021 | - | $9.91 M(+18.1%) |
| Mar 2021 | - | $8.39 M(-3.0%) |
| Dec 2020 | $26.67 M(+125.5%) | $8.65 M(+24.1%) |
| Sep 2020 | - | $6.97 M |
| Dec 2019 | $11.82 M | - |
FAQ
- What is Entrada Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Entrada Therapeutics?
- What is Entrada Therapeutics annual operating expenses year-on-year change?
- What is Entrada Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly operating expenses year-on-year change?
What is Entrada Therapeutics annual total operating expenses?
The current annual operating expenses of TRDA is $132.18 M
What is the all time high annual operating expenses for Entrada Therapeutics?
Entrada Therapeutics all-time high annual total operating expenses is $132.18 M
What is Entrada Therapeutics annual operating expenses year-on-year change?
Over the past year, TRDA annual total operating expenses has changed by +$34.93 M (+35.92%)
What is Entrada Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of TRDA is $41.23 M
What is the all time high quarterly operating expenses for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly total operating expenses is $41.27 M
What is Entrada Therapeutics quarterly operating expenses year-on-year change?
Over the past year, TRDA quarterly total operating expenses has changed by +$11.51 M (+38.71%)